10/14/2026
Coya today announced plans to initiate an open-label extension (OLE) of the Phase 2/3 ALSTARS Trial evaluating COYA 302 for the treatment of amyotrophic lateral sclerosis ( ).
We plan to initiate the OLE in response to requests from ALSTARS investigators and study participants. “The strong interest from investigators and participants in continuing treatment beyond the current 48-week study period underscores the importance of providing continued access to COYA 302 for eligible participants in the ALSTARS trial,” said Dr. Fred Grossman, DO, FAPA, our President and Chief Medical Officer.
For more details: https://www.businesswire.com/news/home/20261014378134/en/Coya-to-Initiate-Open-Label-Extension-of-Phase-23-ALSTARS-Trial-of-COYA-302-in-ALS